• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Development of microRNA-based therapeutics for central nervous system diseases
Eur J Pharmacol. 2023 Aug 2:175956. doi: 10.1016/j.ejphar.2023.175956. Online ahead of print.ABSTRACTMicroRNA (miRNA)-mediated gene silencing is a method of RNA interference in which a miRNA binds to messenger RNA sequences and regulates target gene expression. MiRNA-based therapeutics have shown promise in treating a variety of central nervous system diseases, as verified by results from diverse preclinical model organisms. Over the last decade, several miRNA-based therapeutics have entered clinical trials for various kinds of diseases, such as tumors, infections, and inherited diseases. However, such clinical trials for ...
Source: European Journal of Pharmacology - August 4, 2023 Category: Drugs & Pharmacology Authors: Siqi Xia Chaoran Xu Fuyi Liu Gao Chen Source Type: research

Multi-disciplinary Approach for Drug and Gene Delivery Systems to the Brain
AAPS PharmSciTech. 2021 Dec 3;23(1):11. doi: 10.1208/s12249-021-02144-1.ABSTRACTDrug delivery into the brain has for long been a huge challenge as the blood-brain barrier (BBB) offers great resistance to entry of foreign substances (with drugs inclusive) into the brain. This barrier in healthy individuals is protective to the brain, disallowing noxious substances present in the blood to get to the brain while allowing for the exchange of small molecules into the brain by diffusion. However, BBB is disrupted under certain disease conditions, such as cerebrovascular diseases including acute ischemic stroke and intracerebral ...
Source: AAPS PharmSciTech - December 4, 2021 Category: Drugs & Pharmacology Authors: Nkafu Bechem Ndemazie Andriana Inkoom Ellis Fualefeh Morfaw Taylor Smith Monica Aghimien Dexter Ebesoh Edward Agyare Source Type: research

Development of Biomembrane-mimetic Nanoparticles for the Treatment of Ischemic Stroke
Yakugaku Zasshi. 2021;141(9):1071-1078. doi: 10.1248/yakushi.21-00114.ABSTRACTIncrease in vascular permeability of the blood-brain barrier (BBB) is a distinct pathology following ischemic stroke. In previous studies, we demonstrated that liposomal drug delivery system (DDS)-based delivery of neuroprotectants is useful for treating cerebral ischemia/reperfusion injury. Additionally, our previous studies reported that combination therapy with liposomal fasudil plus tissue plasminogen activator (t-PA), a thrombolytic agent, brings about decrease in the risk of t-PA-derived cerebral hemorrhage and prolong the therapeutic time ...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - September 2, 2021 Category: Drugs & Pharmacology Authors: Tatsuya Fukuta Source Type: research

Pages: 1  2  3